Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 4/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 7/20 | 0.33 |
| ▸ | CDK2 | P24941 | 7/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.31 |
| ▸ | SORD | Q00796 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28850795 | 0.80 | RPS6KA5 (0.44) | RPS6KA5TRPV1PTK2CDC7CDK2 | |
| SCHEMBL3327820 | 0.71 | PIK3CA (0.46) | CDK2 | |
| SCHEMBL19100953 | 0.69 | CDC7 (0.68) | RPS6KA5CDC7CDK2 | |
| SCHEMBL3325800 | 0.68 | RPS6KA5 (0.39) | RPS6KA5TRPV1SORD | |
| SCHEMBL17601089 | 0.68 | RPS6KA5 (0.45) | RPS6KA5TRPV1PTK2CDC7CDK2 | |
| SCHEMBL19100396 | 0.68 | CDC7 (0.68) | RPS6KA5PTK2CDC7CDK2MAP3K14 | |
| SCHEMBL8192197 | 0.67 | CYP3A4 (0.59) | RPS6KA5 | |
| SCHEMBL1613026 | 0.66 | CDC7 (0.70) | RPS6KA5TRPV1PTK2CDC7CDK2 | |
| SCHEMBL6039615 | 0.66 | ROCK1 (0.68) | RPS6KA5CDK2ROCK1 | |
| SCHEMBL19211560 | 0.66 | KDR (0.52) | RPS6KA5PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| CN-101128440-A | Hydrazinomethyl, hydrazonomethyl and 5-membered heterocyclic compounds as mTOR inhibitors and their use as anti-cancer agents | KUDOS PHARM LTD (GB) | 2008-02-20 | — | — | CN | disclosed |
| EP-1877388-A2 | HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | Kudos Pharmaceuticals Ltd (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060199804-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199804-A1 | Compounds | CA4, CA6, CYP2B6 | RPS6KA5 2478/4885TRPV1 2522/4885PTK2 3657/4885 |
| US-20100130473-A1 | COMPOUNDS | CA6, CYP2B6, CA4 | RPS6KA5 1985/4885TRPV1 2461/4885PTK2 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.